Status:
COMPLETED
24-hour IOP-lowering Effect of Brimonidine 0.1%
Lead Sponsor:
Allergan
Conditions:
Open-angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
Eligibility Criteria
Inclusion
- patients with open-angle glaucoma or ocular hypertension
Exclusion
- allergy to brimonidine
- inability to complete 24 hour stay for monitoring
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00457795
Start Date
December 1 2006
End Date
February 1 2009
Last Update
November 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Diego, California, United States